Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): appeal

An appeal has been lodged for this appraisal. Below are the papers related to this appeal.

For more information on the Technology Appraisal Appeal Process, go to the appeal hearings homepage.

The Institute have received one appeal from Roche Products Ltd

The Appeal hearing is taking place at NICE, Level 1a, City Tower, Piccadilly Plaza, Manchester M1 4BD on Thursday 8 September 2011 at 10am.

This page was last updated: 31 October 2011

Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2